Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Jan 31, 2013 (14 years ago)

Suprax (cefixime for oral suspension)

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Discoloration; Product may not meet specifications for color description once reconstituted.

Cause type: Failed specification

A physical or chemical test other than potency, dissolution, impurity or stability failed - pH, viscosity, appearance, tablet integrity, fill volume. A product outside its own specification may not perform as designed, even if the active ingredient is present. All failed specification recalls.

What was recalled

Suprax (cefixime for oral suspension) USP, 100 mg/5 mL, 50 mL bottles (when reconstituted), Manufactured for Lupin Pharmaceuticals, Inc. 111 South Calvert Street, Baltimore, MD 21202, Manufactured by Lupin Limited Mumbai 400 058 India, NDC 68180-202-03.

Affected NDC 68180-0202-03

Compare with the code on your package — it is the most precise check available.

Drug: Cefixime

Recalling firm
Lupin Pharmaceuticals Inc.
NDC code
68180-202-03
Origin
MD, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-264-2013 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Cefixime recalls

See all
Class II · Moderate risk

Cefixime for Oral Suspension USP

Subpotent Drug- An out of specification ( OOS ) result observed in assay test during 18-month long term stability study.

Terminated Wrong potency / content Lupin Pharmaceuticals Inc. NDC 68180-405-01 D-0648-2024

Other recalls by Lupin Pharmaceuticals Inc.

All 2013 recalls